In a year defined by landmark decisions, impactful announcements and new standards, clarity in the patent world comes as a welcome relief. It arrived via a federal circuit court decision in August 2024 that settled certain...more
5/13/2025
/ Appeals ,
CAFC ,
Double Patent ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inventions ,
New Guidance ,
Obviousness-Type Double Patenting (ODP) ,
Patent Litigation ,
Patent Validity ,
Patents ,
Prior Art ,
Thought Leadership
Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms of heart failure. MSN submitted an Abbreviated New Drug Application seeking...more
3/11/2025
/ Abbreviated New Drug Application (ANDA) ,
Claim Construction ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Intellectual Property Protection ,
Novartis ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular
On June 22, Senator Thom Tillis (R – NC) and Senator Chris Coons (D – DE) introduced the Patent Eligibility Restoration Act of 2023, which seeks to eliminate all judicial exceptions to patent eligibility. The bill proposes...more